Dr Choueiri on the Phase 3 TiNivo-2 Study in Pretreated Advanced RCC

Toni K. Choueiri, MD, director, Lank Center for Genitourinary Oncology, co-leader, Kidney Cancer Program, senior physician, Dana-Farber Cancer Institute, Jerome and Nancy Kohlberg Chair and Professor of Medicine, Harvard Medical School, discusses the phase 3 TiNivo-2 study (NCT04987203) in pretreated advanced renal cell carcinoma (RCC).

TiNivo-2 is a randomized trial comparing tivozanib (Fotivda) plus nivolumab (Opdivo) vs tivozanib monotherapy in patients with RCC following disease progression on 1 or 2 prior lines of therapy, including an immune checkpoint inhibitor. The study is fully accrued, and findings are expected later this year; the results could potentially be practice altering if a benefit is observed with immune checkpoint inhibitor rechallenge, Choueiri says.